"With the approval of ONIVYDE, we have the first and only treatment approved for metastatic adenocarcinoma following gemcitabine-based therapy, and an option that may improve patient survival.
This is an important advance for the field of oncology and the lives of those impacted by pancreatic cancer." The Marketing Authorization is based on the data from the pivotal, Phase 3 NAPOLI-1 study that demonstrated ONIVYDE combined with 5-FU/LV significantly improved overall survival (OS) (primary endpoint), as well as progression-free survival (PFS) and objective response rate (ORR) relative to the 5-FU/LV control arm (secondary endpoints).
Phase 2 will include badges, learning plans linked to accredited competency frameworks, wikis (for collaborative content development) and new content from international thought leaders and academics.
The site will continue to follow our ethos of free work and life learning, and the redevelopment and ongoing management will be delivered by our partner Accipio.
Effective treatment options for patients with r/r ALL are limited.
In pediatric and young adult patients with B-cell ALL that have relapsed multiple times or become refractory to treatment, the five-year disease-free survival is less than 10-30%.
Very soon we will be launching a new visual identity, refreshing the design of the site and adding lots of new functionality to enhance your learning experience and the website's usefulness.Adult Aspies, like kids with the syndrome, have trouble deciphering the normal rules of society, which impacts their home, work and social lives. Assessment—Aspergers is a clinical diagnosis versus medical. Psychological interviewing that includes medical, psychiatric and childhood history contributes to an Aspergers diagnosis.Aspergers is considered a pervasive developmental disorder according the DSM.In the trial, the most common Grade 3 or higher adverse events with greater than five percent difference in patients receiving ONIVYDE and 5-FU/LV, versus 5-FU/LV alone, were neutropenia, fatigue, diarrhoea, and vomiting. About ONIVYDE (nal-IRI) ONIVYDE is a first-of-its-kind formulation (encapsulation) of irinotecan in a long-circulating liposomal form designed to improve delivery of length of tumor exposure to irinotecan and its active metabolite SN-38. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options.